Drug Trial Radar · NCT04173650
MSC EVs in Dystrophic Epidermolysis Bullosa
Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
8
Planned (sponsor's estimate)
Start
Aug 13, 2024
Primary completion
Sep 2025
Study completion Mar 2026
Sponsor
- Lead sponsor
- Aegle TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 22, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
INVESTIGATIONAL PRODUCT: AGLE-102 is an allogeneic extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). INDICATION AND RATIONALE: The aim of the study is to assess the safety and efficacy of AGLE-102 in the treatment of lesions in subjects with Epidermolysis Bullosa (EB). STUDY DESIGN: This is a phase 1/2A, randomized, multi-center, study to assess the effectiveness and safety of AGLE-102 on lesions in subjects with EB.
Conditions
- Dystrophic Epidermolysis Bullosa
Interventions
AGLE-102Drug
Extracellular vesicles from bone marrow derived mesenchymal stem cells - up to six topical administrations
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent Adverse EventsTime frame: 22 weeks
- Wound healing improvementTime frame: 10 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona · Recruiting
USC /Norris Comprehensive Cancer Center University of Southern California
Los Angeles, California · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.